GlassScriptPhysician profile
Taylor D Todd
NPI 1831549906
$5,362.16
in general payments reported to CMS, 2019-2025
22 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $1,278 · 2023: $719 · 2024: $2,136 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.86 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,008.64 | 2022-2025 | Bimzelx |
| Abbvie INC. | $978.99 | 2021-2025 | |
| Incyte Corporation | $534.97 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $438.13 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $371.94 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $353.88 | 2021-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $276.08 | 2021-2025 | |
| Amgen INC. | $244.07 | 2022-2024 | Otezla |
| Pfizer INC. | $219.63 | 2021-2024 | |
| Genzyme Corporation | $189.72 | 2021-2024 | |
| Janssen Biotech, INC. | $148.79 | 2021-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $142.58 | 2021-2022 | |
| Lilly USA, LLC | $74.56 | 2022-2024 | Ebglyss, Olumiant, Taltz |
| Galderma Laboratories, L.P. | $74.56 | 2021-2025 | Aklief, Nemluvio |
| Revance Therapeutics, INC. | $67.05 | 2024 | Daxxify |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $53.11 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.61 | 2021-2023 | Jublia |
| Organon LLC | $41.23 | 2024-2025 | |
| Almirall LLC | $34.21 | 2022 | |
| Vyne Pharmaceuticals INC. | $22.88 | 2021 | |
| Biofrontera INC. | $21.73 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $14.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.